Table 1.
Main characteristics of the studies included in the meta-analysis.
| First author | Year | Patient source | Sample size | Cancer type | Method | Expression location | Cut-off value | Median(range) months | Outcome | M/U | HR ratio | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Li et al. (10) | 2012 | Chinese | 99 | HCC | IHC | Tumor cell | Median level | NA | OS | U | Survival curve | 6 |
| Zhuang et al. (11) | 2012 | Chinese | 30 | NSCLC | IHC | Tumor cell | ≥25% positivity cell | 34 (1-78) | OS | M | Reported | 9 |
| Jiang et al. (28) | 2013 | Chinese | 305 | GC | IHC | Tumor cell | HSCORE>0 | 40 (3-135) | OS | U | Survival curve | 8 |
| Cao et al. (29) | 2013 | Chinese | 43 | Cervical cancer | IHC | Tumor cell | Score≥2 | 45.2 (5-60) | OS | U | Survival curve | 6 |
| Yang et al. (13) | 2015 | Chinese | 100 | BUC | IHC | Tumor cell | HSCORE≥100 | 44 (3-60) | DFS | U | Survival curve | 8 |
| Yang et al. (13) | 2015 | Chinese | 100 | BUC | IHC | Tumor cell | HSCORE≥100 | 44 (3-60) | OS | U | Survival curve | 8 |
| Zhou et al. (30) | 2015 | Chinese | 201 | CRC | IHC | Tumor cell | HSCORE≥200 | 61 (2-103) | OS | U | Survival curve | 8 |
| Komohara et al. (12) | 2015 | Japanese | 91 | RCC | IHC | Tumor cell | Score≥1 | NA | OS | U | Survival curve | 6 |
| Komohara et al. (12) | 2015 | Japanese | 91 | RCC | IHC | Tumor cell | Score≥1 | NA | PFS | U | Survival curve | 6 |
| Shan et al. (31) | 2016 | Chinese | 64 | ESCC | IHC | Tumor cell | Score>3 | 31 (7-105) | OS | U | Survival curve | 8 |
| Hou et al. (32) | 2017 | Chinese | 45 | ESCC | IHC | Tumor cell | Score≥3 | NA | OS | M | Reported | 6 |
| Peng et al. (33) | 2017 | Chinese | 50 | Pancreatic cancer | IHC | Tumor cell | Score≥3 | 10.3 | OS | U | Survival curve | 7 |
| Wu et al. (14) | 2017 | Chinese | 139 | Prostate cancer | IHC | Tumor cell | Score≥6 | 22.1 | OS | U | Survival curve | 7 |
| Byun et al. (34) | 2018 | Korea | 109 | Breast cancer | IHC | TIL | Score≥2 | 76 (6-131) | DFS | M | Reported | 8 |
| Byun et al. (34) | 2018 | Korea | 109 | Breast cancer | IHC | TIL | Score≥2 | 76 (6-131) | OS | M | Reported | 8 |
| Duan et al. (35) | 2018 | Chinese | 95 | ESCC | IHC | TIL | ≥1% positivity cell | 32 (3-84) | OS | U | Survival curve | 7 |
| Wang et al. (9) | 2018 | Chinese | 587 | GC | IHC | TIL | Median | 48 (1-117) | OS | M | Reported | 8 |
| Su et al. (41) | 2018 | Chinese | 223 | NSCLC | IHC | Tumor cell +TIL | ≥24% on tumor cell and/or≥11% on TIL | 76 (4-101) | DFS | M | Reported | 8 |
| Su et al. (41) | 2018 | Chinese | 223 | NSCLC | IHC | Tumor cell +TIL | ≥24% on tumor cell and/or≥11% on TIL | 76 (4-101) | OS | M | Reported | 8 |
| Cheng et al. (36) | 2018 | Chinese | 42 | Breast cancer | IHC | Tumor cell | Score>1 | NA | OS | U | Survival curve | 8 |
| Jia et al. (42) | 2019 | Poland | 139 | NSCLC | IHC | Tumor cell | >5% on tumor cell | NA | DFS | U | Survival curve | 7 |
| Jia et al. (42) | 2019 | Poland | 139 | NSCLC | IHC | TIL | >10% on TIL | NA | DFS | U | Survival curve | 7 |
| Jia et al. (42) | 2019 | Poland | 139 | NSCLC | IHC | Tumor cell | >5% on tumor cell | NA | OS | U | Survival curve | 7 |
| Jia et al. (42) | 2019 | Poland | 139 | NSCLC | IHC | TIL | >10% on TIL | NA | OS | U | Survival curve | 7 |
| Zhao et al. (37) | 2019 | Chinese | 183 | ESCC | IHC | TIL | Score>3 | NA | DFS | M | Reported | 8 |
| Zhao et al. (37) | 2019 | Chinese | 183 | ESCC | IHC | TIL | Score>3 | NA | OS | M | Reported | 8 |
| Hong et al. (38) | 2019 | Korea | 396 | ESCC | IHC | TIL | ≥1% | 24.8 (0.5–210) | DFS | M | Reported | 9 |
| Hong et al. (38) | 2019 | Korea | 396 | ESCC | IHC | TIL | ≥1% | 24.8 (0.5–210) | OS | M | Reported | 9 |
| Pu et al. (39) | 2019 | Chinese | 38 | Osteosarcoma | IHC | Tumor cell | Score >1.1 | NA | OS | U | Survival curve | 8 |
| Zhou et al. (40) | 2019 | Chinese | 93 | Skull base chordoma | IHC | TIL | Score>1 | 36.9 (14-66) | DFS | M | Reported | 9 |
| Zhou et al. (40) | 2019 | Chinese | 93 | Skull base chordoma | IHC | TIL | Score≥2 | 36.9 (14-66) | OS | M | Reported | 9 |
HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer; GC, gastric cancer; BUC, bladder urothelial carcinoma; CRC: colorectal cancer; RCC: renal cell carcinoma; ESCC, esophageal squamous cell carcinoma; IHC, Immunohistochemistry; TIL, tumor infiltrating lymphocyte; DFS, disease-free survival; PFS, progression-free survival; OS, overall survival; M, multivariate analysis; U, univariate analysis; HR, hazard ratio; NA, not available; NOS: Newcastle-Ottawa Scale.